BridgeBio Pharma Inc (BBIO)
27.86
-1.14
(-3.93%)
USD |
NASDAQ |
Jun 14, 16:00
27.89
+0.03
(+0.11%)
Pre-Market: 20:00
BridgeBio Pharma Free Cash Flow (Quarterly): -221.03M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -221.03M |
December 31, 2023 | -125.25M |
September 30, 2023 | -145.66M |
June 30, 2023 | -113.78M |
March 31, 2023 | -144.33M |
December 31, 2022 | -94.04M |
September 30, 2022 | -135.92M |
June 30, 2022 | -34.36M |
March 31, 2022 | -161.49M |
December 31, 2021 | -136.43M |
September 30, 2021 | -163.02M |
June 30, 2021 | -94.00M |
March 31, 2021 | -152.73M |
Date | Value |
---|---|
December 31, 2020 | -98.41M |
September 30, 2020 | -132.23M |
June 30, 2020 | -88.20M |
March 31, 2020 | -88.40M |
December 31, 2019 | -75.45M |
September 30, 2019 | -50.38M |
June 30, 2019 | -68.83M |
March 31, 2019 | -61.57M |
December 31, 2018 | -47.16M |
September 30, 2018 | -38.93M |
June 30, 2018 | -35.61M |
March 31, 2018 | -33.13M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-221.03M
Minimum
Mar 2024
-34.36M
Maximum
Jun 2022
-116.20M
Average
-119.52M
Median
Free Cash Flow (Quarterly) Benchmarks
Alnylam Pharmaceuticals Inc | -94.49M |
Pfizer Inc | 386.00M |
Arcellx Inc | -38.34M |
Biomarin Pharmaceutical Inc | 12.87M |
Viking Therapeutics Inc | -6.134M |